
Allo CAR T Myeloma Therapies with Jesus Berdeja, MD, Sarah Cannon Research Institute
TO JOIN THE SHOW BY PHONE, PLEASE CALL (347) 637-2631
CAR T therapies are expanding as multiple myeloma treatment options. In addition to the two currently FDA approved CAR T therapies (Abecma and Carvykti) which use a patient's own T cells in a production process, new allo (off-the-shelf) options are being developed in clinical trials. Dr. Jesus Berdeja is one of the leading CAR T experts in multiple myeloma and in this episode, he will share the current development taking place for allo CAR T therapies. Join us to learn more about this exciting field in myeloma research which may provide faster and more available treatment options for patients.
Thanks to our episode sponsor

Note: Myeloma Crowd Radio is becoming HealthTree Podcast for Multiple Myeloma
Jesus Berdeja, MD
Sarah Cannon Research Institute
Interview Date: June 27, 2022
CAR T therapy is both FDA approved and continues to be in development in clininical trials. While the Abecma and CARVYKTI products used commercially are autologous (meaning they use a patients' own T cells), a whole new set of CAR T products in developmnet are allogeneic, or "off-the-shelf." These allogeneic CAR T options could provide faster access, less bridging therapy and better availability. Learn more from CAR T myeloma expert Jesus Berdeja, MD about this class of new myeloma treatments in this important show.
Thanks to our episode sponsor

Dr. Jesus Berdeja
Jennifer Ahlstrom
Myeloma survivor, patient advocate, wife, mom of 6.
